The delivery challenge is posed by the blood–brain barrier (BBB), which prevents around 95% of small molecules, and almost all therapeutic biologics, from leaving the bloodstream and entering ...

ABL Bio’s first-in-class bispecific antibodies for Parkinson’s disease combine unprecedented blood–brain barrier penetration with a robust mechanism of action for improved therapeutic efficacy.

The blood–brain barrier (BBB) is meant to protect the brain from noxious agents; however, it also significantly hinders the delivery of therapeutics to the brain. Several strategies have been ...